Retrophin (NASDAQ:RTRX) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Saturday.

RTRX has been the subject of a number of other reports. BMO Capital Markets restated a “buy” rating and issued a $44.00 price objective on shares of Retrophin in a report on Friday, October 6th. Zacks Investment Research lowered shares of Retrophin from a “hold” rating to a “strong sell” rating in a report on Tuesday, November 14th. Finally, BidaskClub lowered shares of Retrophin from a “buy” rating to a “hold” rating in a report on Saturday, December 30th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $44.00.

Retrophin (NASDAQ RTRX) opened at $22.79 on Friday. Retrophin has a 1-year low of $15.55 and a 1-year high of $26.44. The firm has a market cap of $939.82 and a P/E ratio of -15.09. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.88 and a quick ratio of 3.83.

Retrophin (NASDAQ:RTRX) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.21). Retrophin had a negative return on equity of 10.13% and a negative net margin of 33.79%. The firm had revenue of $40.34 million during the quarter, compared to analysts’ expectations of $40.51 million. During the same quarter in the previous year, the firm earned ($0.09) earnings per share. Retrophin’s revenue was up 18.8% on a year-over-year basis. analysts anticipate that Retrophin will post -1.24 earnings per share for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the business. Nationwide Fund Advisors raised its stake in Retrophin by 14.6% during the 2nd quarter. Nationwide Fund Advisors now owns 59,424 shares of the biopharmaceutical company’s stock valued at $1,152,000 after buying an additional 7,583 shares during the last quarter. Prudential Financial Inc. purchased a new stake in Retrophin during the 2nd quarter valued at $775,000. Schwab Charles Investment Management Inc. raised its stake in Retrophin by 35.7% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 277,688 shares of the biopharmaceutical company’s stock valued at $5,385,000 after buying an additional 73,067 shares during the last quarter. Strs Ohio purchased a new stake in Retrophin during the 3rd quarter valued at $908,000. Finally, JPMorgan Chase & Co. raised its stake in Retrophin by 4.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 137,526 shares of the biopharmaceutical company’s stock valued at $2,667,000 after buying an additional 5,674 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: “Retrophin (RTRX) Cut to Sell at ValuEngine” was published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.watchlistnews.com/retrophin-rtrx-cut-to-sell-at-valuengine/1840746.html.

Retrophin Company Profile

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.